Concomitant gemcitabine, cisplatin, anastrazole, and zoledronic acid in HER2-negative metastatic breast cancer in postmenopausal women.

Abstract

1129 Background: There is no preclinical or clinical evidence against the concomitant use of aromatase inhibitors with systemic chemotherapy in breast cancer. Despite this fact it is rarely used in clinical practice today. Aromatase inhibitors have the significant therapeutic contribution in the management of hormone responsive disease in postmenopausal women and ideally their use shall not be delayed till the completion of chemotherapy. Therefore, we have designed this study to evaluate the efficacy and toxicity of concomitant gemcitabine, cisplatin, anastrazole, and zoledronic acid. Methods: Patients with visceral or visceral and bone metastases were included. Postmenopausal, ER-/PR-positive and HER2neu-negative patients with a KPS of > 70, adequate marrow, hepatic, and renal function were enrolled. Metastatic brain disease and bone as the only site of disease was excluded. Gemcitabine 1,250 mg/m2 was given on day 1 and 8, with cisplatin 70 mg/m2 on day one of three weekly cycles. Anastrazole 1 mg was g...